DRKS00022788进行中（未招募）3 期
Clinical Trial for the treatment of acute myeloid leukaemia in children and adolescents - AML-BFM 2012
GPOH gemeinnützige GmbH AML-BFM Studienzentrale0 个研究点目标入组 164 人开始时间: 2021年3月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 164
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- one 至 18 Years（—）
- 性别
- All
入选标准
- •Diagnosis of an AML (It. WHO classification 2008)
- •Acute leukemia of ambiguous lineage (MPAL; It. WHO classifiction 2008: acute undifferenziated leukemia (AUL, bilineal leukemia; biphenotype leukemias, dominant myelogenous; lineage switch)
- •Ages 0 to 18 years
- •Informed consent for study participation and data handling
排除标准
- •Existing syndromes which exlude treatment
- •Patients with trisomy 21 and ML-DS and/or transient myeloproliferativem syndrome (link to the TMD-prevention study or the ML-DS 2006 study)
- •Patients with an acute promyeloblastic leukemia (APL), AML with t(15;17)
- •Treatment related AML
- •Refusal of treatment/ missing informed consent to treatment or protocol
- •Participation in another clinical trial with an intervention interfering with the aims of this trial
- •breast feeding
- •Known allergic reaction to the study drug
- •Patients of child-bearing age who decline a pregnancy test or refuse appropriate prevention of pregnancy.
- •Previous-therapy with cytostatistic medicines of more than 14 days.
研究者
相似试验
进行中（未招募）
1 期
Clinical trials for the treatment of acute myeloid leukemia in children and adolescentsMedDRA version: 18.1 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 100000004864AMLEUCTR2013-000018-39-ATGesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH gGmbH)625
进行中（未招募）
1 期
Clinical trials for the treatment of acute myeloid leukemia in children and adolescentsAMLMedDRA version: 18.0 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 100000004864EUCTR2013-000018-39-DEGesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH gGmbH)625
招募中
3 期
Phase III Clinical Trial for the Treatment of Myeloid Leukemia in Children with Down Syndrome 2018C92Myeloid leukaemiaDRKS00023849Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH)150
进行中（未招募）
不适用
TREATMENT OF PRIMARY ACUTE MYELOID LEUKEMIA WITH THE COMBINATION OF IDARUBICIN, CYTARABINE AND GEMTUZUMAB OZOGAMYCIN (MYLOTARG) ASSOCIATED OR NOT TO G-CSF PRIMING: PROSPECTIVE STUDY OF EFFICACY AND TOXICITY.Tratamiento de la leucemia mieloide aguda de novo con la combinación de idarrubicina, citarabina y gemtuzumab ozogamicina (Mylotarg), asociada o no a priming con G-CSF. Estudio prospectivo de eficacia y toxicidad. - Farmacoterapia de inducción con Mylotarg en LMAeucemia Mieloide Aguda Primaria de novoMedDRA version: 9.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaEUCTR2007-006295-11-ESInstituto de Investigación del Hospital de la Santa Creu i Sant Pau
进行中（未招募）
不适用
A phase III trial in adult acute myelogenous leukemia AML comparing 1 standard-dose versus high-dose remission induction therapy and 2 , within a risk-oriented postremission strategy, an autologous blood stem cell transplantation versus an autologous blood stem cell-supported multicycle high-dose program Protocol NILG-AML 02/06 . - NDPATIENT WHIT LMAMedDRA version: 8.1Level: HLTClassification code 10024291Term: Leukaemias acute myeloidEUCTR2006-003817-42-ITAZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE